Firmonertinib

DB16087InvestigationalSmall molecule

Alflutinib is under investigation in clinical trial NCT03452592 (Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients With T790M).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₈H₃₁F₃N₈O₂ · 568.605 g/mol (avg)
Also known as: Alflutinib · Furmonertinib
Code names: AST-2818

Resolves to

Compound

UNIIA49A7A5YN4CAS1869057-83-9ChEMBLCHEMBL4297258

Structure

InChIKeyGHKOONMJXNWOIW-UHFFFAOYSA-NSMILESCN(C)CCN(C)C1=NC(OCC(F)(F)F)=C(NC2=NC=CC(=N2)C2=CN(C)C3=C2C=CC=C3)C=C1NC(=O)C=C

Targets

P00533EGFR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

66Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Firmonertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account